Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 17 citing articles:

Impact of structural modifications of IgG antibodies on effector functions
Timon Damelang, Maximilian Brinkhaus, Thijs L. J. van Osch, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 30
Structure and function of therapeutic antibodies approved by the US FDA in 2023
William R. Strohl
Antibody Therapeutics (2024) Vol. 7, Iss. 2, pp. 132-156
Open Access | Times Cited: 7
Preventing RSV Infection in Children: Current Passive Immunizations and Vaccine Development
Pius I. Babawale, Iván Martínez-Espinoza, Andrew Mitchell, et al.
Pathogens (2025) Vol. 14, Iss. 2, pp. 104-104
Open Access
Combinatorial Fc modifications for complementary antibody functionality
Yannic C. Bartsch, Nicholas E. Webb, Eleanor Burgess, et al.
mAbs (2025) Vol. 17, Iss. 1
Open Access
Longitudinal humoral analysis in RSV-infected infants identifies pre-existing RSV strain-specific G and evolving cross-reactive F antibodies
Nadège Nziza, Wonyeong Jung, Maanasa Mendu, et al.
Immunity (2024) Vol. 57, Iss. 7, pp. 1681-1695.e4
Open Access | Times Cited: 2
Neutralizing activity of anti-respiratory syncytial virus monoclonal antibody produced in Nicotiana benthamiana
Nuttapat Pisuttinusart, Kaewta Rattanapisit, Chanya Srisaowakarn, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 1
Independent Analysis of the Results of the First Infant Immunization Campaign with Beyfortus® (Nirsevimab, Monoclonal Antibody against RSV, Bronchiolitis Virus): Mixed Results, Identification of Biases and Possible Role and Mechanisms of ADE (Antibod
Hélène Banoun
(2024)
Open Access | Times Cited: 1
Analysis of Beyfortus® (Nirsevimab) Immunization Campaign: Effectiveness, Biases, and ADE Risks in RSV Prevention
Hélène Banoun
(2024)
Open Access | Times Cited: 1
RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing
Deidre Wilkins, Ulrika Wählby Hamrén, Yue Chang, et al.
PEDIATRICS (2024) Vol. 154, Iss. 5
Closed Access | Times Cited: 1
Independent Analysis of the Results of the First Infant Immunization Campaign with Beyfortus® (Nirsevimab, Monoclonal Antibody Against RSV Bronchiolitis Virus): Mixed Results, Identification of Biases, and Possible Role and Mechanisms of ADE (Antibody Dependent Enhancement)
Hélène Banoun
(2024)
Open Access
Multiple Questions About Protection From Respiratory Syncytial Virus
Stanley A. Plotkin
The Pediatric Infectious Disease Journal (2024) Vol. 43, Iss. 9, pp. 867-868
Closed Access
The Evolving Maternal Vaccine Platform
Rebecca M Adams, Bernard Gonik
Reproductive Medicine (2024) Vol. 5, Iss. 3, pp. 154-171
Open Access
Fc‐FcγR interactions during infections: From neutralizing antibodies to antibody‐dependent enhancement
Julia E. Edgar, Stylianos Bournazos
Immunological Reviews (2024)
Open Access
Analysis of Beyfortus® (Nirsevimab) Immunization Campaign: Effectiveness, Biases, and ADE Risks in RSV Prevention
Hélène Banoun
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 9, pp. 10369-10395
Open Access
First real-world data on universal respiratory syncytial virus prophylaxis with Nirsevimab in infants.
Andrea Orsi, Marianna Scarpaleggia, Vincenzo Baldo, et al.
PubMed (2024) Vol. 65, Iss. 2, pp. E172-E187
Closed Access
Impfung gegen RSV-Infektionen – Update und Ausblick
Till Koch, Robin Kobbe
DMW - Deutsche Medizinische Wochenschrift (2024) Vol. 149, Iss. 22, pp. 1341-1347
Closed Access
A molecular perspective for the development of antibodies against the human respiratory syncytial virus
Ricardo A. Loaiza, Robinson Ramı́rez, Javiera Sepúlveda-Alfaro, et al.
Antiviral Research (2023) Vol. 222, pp. 105783-105783
Closed Access | Times Cited: 1
Page 1

Scroll to top